ImpediMed Limited
Suite 31C, 12-18 Tryon Rd
Lindfield NSW 2070
Australia
E: investorrelations@impedimed.com
W : impedimed.com

18 November 2026

Companies Announcements Office
Australian Securities Exchange

2026 Annual General Meeting – CEO's Presentation

ImpediMed Limited (**ImpediMed**) (ASX:IPD) provides the attached CEO's presentation to be delivered at today's Annual General Meeting commencing at 11.00am AEDT.


Approved for release by the Board of ImpediMed Limited.

For more information, contact Leanne Ralph, Company Secretary, at leanne.ralph@bellev.com.au

impedimed®

ImpediMed Limited 2026

Annual General Meeting



18 November 2026 | ASX: IPD

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed.
©2026 ImpediMed Limited.

CEO’s Presentation

Mr Erik Anderson

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited.

The SOZO® Digital Health Platform Value Proposition

Strong foundation

- Best-in-class, FDA-cleared, TGA-cleared, and CE-Marked cloud-based digital health platform delivering body composition and fluid outputs, led by new Executive Leadership.

Addressing fast growing healthcare segments

Cancer Survivorship: Updated standards and recent FDA-clearance solidifying growth opportunity.

Heart Health: Generating clinical evidence and securing FDA indications to address broad patient population.

Weight Management & Body Composition: FDA indications addresses gaps across focused market segments.

Leveraging investment across multiple indications

- SOZO Pro and SOZO investment in multiple FDA clearances in Lymphoedema, BodyComp and Heart Failure, and is the only BIS device cleared for unhealthy patients and patients with implantable cardiac devices.
- 662 devices in leading US healthcare customers and 27 IDN MSAs form strong platform for expansion:
  - 18 of the top 25 US hospitals
  - 27 MSAs with major IDNs provide more than 1,400 hospital opportunities.
  - 541 NAPBC sites
  - Customer Success focus on program health and expansion opportunities



Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited.

The Cancer Survivorship Challenge

Lymphedema is reversible at the subclinical stage, and weight alone misses muscle loss[1,2]

BREAST CANCER

4.3M
US breast cancer survivors[3]

1 in 5
develop lymphedema without BIS early detection[1]

1 in 3
develop sarcopenia in chemo, doubling toxicity odds[4,5]

$22 - 40K
Annual cost of treatment per US patient[6]

With early detection, **92% of patients didn't progress to chronic lymphedema**[1]

1. Ridner SH, et al. A Comparison of Bioimpedance Spectroscopy or Tape Measure Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention. Lymphatic Research and Biology. 2022. (PREVENT)
2. Shachar SS, et al. Prognostic value of sarcopenia in adults with solid tumours. Eur J Cancer. 2016;57:58–67.
3. American Cancer Society. Cancer Treatment & Survivorship Statistics, 2025. Wagle NS, et al. CA Cancer J Clin. 2025.
4. Jang MK, et al. Support Care Cancer. 2024;32:328.
5. Aleixo GFP, et al. Sarcopenia detected with bioelectrical impedance versus CT scan and chemotherapy tolerance in patients with early breast cancer. Breast Cancer. 2023;30(1):101–109.
6. **The Financial Burden Of Lymphedema Treatment On The Patient** Shayan M. Sarrami, MD, **Alexis M. Henderson, MPH**, Benjamin B. Scott, MD, Meeti Mehta, BS, Erica Onuoha, MPH, Carolyn De La Cruz, MD. *University of Pittsburgh Medical Center, Pittsburgh, PA, USA,University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. AAPS, 2025.*

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited.

Beyond Breast Cancer

ALL CANCERS


>18M
US cancer survivors[1]

58%
at risk for developing limb lymphedema[2]

up to 83%
of older patients with cancer have sarcopenia, by cancer type[3]

~60%
of cancer patients report at least moderate fear of recurrence[4]

Patients with sarcopenia before treatment, by cancer type[5]



Rates measured before treatment. In breast cancer, sarcopenia rises to 1 in 3 during chemotherapy.[7]

1. American Cancer Society. Cancer Treatment & Survivorship Facts & Figures 2024–2026. Atlanta: American Cancer Society; 2024.
2. American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022.
3. Sarcopenia among older patients with cancer: a scoping review. J Geriatr Oncol. 2022.
4. Luigjes-Huizer YL, et al. What is the prevalence of fear of cancer recurrence in cancer survivors and patients? Psycho-Oncology. 2022;31:879–892.
5. Couderc AL, et al. Pre-therapeutic sarcopenia among cancer patients: an up-to-date meta-analysis of prevalence and predictive value. Nutrients. 2023;15:1193 (226 studies, 65,936 patients).
6. Jiang Y, et al. Prevalence and prognostic significance of sarcopenia in gynecologic oncology: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2025 (24 studies, 4,136 patients).
7. Jang MK, et al. Support Care Cancer. 2024;32:328.


Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited.

The Leader in Objective Survivorship Monitoring

SOZO® is advancing a new standard for understanding patient health throughout the cancer journey. Through objective insight into fluid status and body composition, we help healthcare providers gain a more complete view of factors that influence treatment tolerance, recovery, function, and long-term survivorship.

By bringing greater clarity to aspects of patient health that are often difficult to recognize early, SOZO® helps care teams better understand patient needs, personalize care with greater confidence, and support patients more effectively throughout treatment and survivorship.

- Earlier Detection
- Smarter Intervention
- Better Long-Term Management




impedimed®

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited.

One Platform. Multiple Dimensions of Patient Health.

L-Dex® and BodyComp™ analyses from the same SOZO® scan.

L-Dex® Analysis




Objective assessment of lymphedema

- ✓ Baseline assessment
- ✓ Routine surveillance
- ✓ Long-term monitoring

Only FDA-cleared BIS for **lymphedema assessment**

BodyComp™ Analysis



A broader view of survivorship health

- ✓ **FluidFit™** – fluid status
- ✓ **TissueFit™** – muscle and fat
- ✓ **CellularFit™** – phase angle and cellular health

Only FDA-cleared BIS for **sarcopenia risk assessment**

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited.

Two Market Segments. Two Roles in Cancer Care.

Academic centers are where cancer care is **invented**.
Community oncology is where most of it is **delivered**.



Academic Cancer Centers

Where care is invented



Community Oncology

Where care is delivered

	Academic Cancer Centers	Community Oncology
Who they are	University-linked hospitals: MD Anderson, Memorial Sloan Kettering, Mayo, Dana-Farber	Local practices close to home: physician-owned, health-system owned, or national networks
Care delivered	Treat, teach and research at once. Run most cutting-edge trials, write the guidelines.	Chemo, infusion, follow-up and survivorship, where the majority of US cancer patients are seen.
Why they matter	**Credibility. We have to win here.**	**Volume and speed. This is where the patients are.**
Right to Win	Standards & Guidelines call for Lymphoedema Surveillance using BIS, with 95%+ national reimbursement coverage.	Lymphoedema + BodyComp with sarcopenia risk assessment flags patients before, during, and after treatment in survivorship, at scale.

Lymphoedema+ Strategy enables our ability to scale to Community Oncology

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited.

The Direction of Survivorship Care

Across oncology, clinical guidelines, accreditation standards, and supportive care initiatives are increasingly aligned around earlier detection, intervention, and long-term survivorship management.

NCCN
Survivorship Guidelines v3.2026

FOCUS

Baseline measurement
Routine screening
Early detection

NAPBC
Lymmphoedema Standard

FOCUS

Standard 5.8 assessment
Survivorship standards
Functional assessment

Commission on Cancer
Exercise Oncology Standard

FOCUS

Exercise Oncology Services
Rehabilitation integration
Supportive care programs

ASCO
Prehabilitation Guidance

FOCUS

Prehabilitation
Early intervention
Patient optimization

SOZO® as the clinical anchor for continuous survivorship care

Earlier detection → **Earlier intervention** → **Longitudinal monitoring**

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited.

Longitudinal Monitoring From Baseline Through Survivorship

A single measurement is a snapshot. Repeated over time, it becomes a trend clinicians can act on.

	Pre-Treatment Baseline	**During Treatment** Surveillance	**Post-Treatment** Recovery	**Long-Term** Survivorship
L-Dex® Analysis Lymphedema Assessment	Pre-op baseline	Detect subclinical change	Trigger intervention	Ongoing surveillance
BodyComp™ Analysis Fluid, Muscle, Fat & Cellular Health	Baseline composition	Track muscle loss	Guide nutrition and exercise	Monitor meaningful change over time


Breast Surgeon | **Medical Oncologist** | **Radiation Oncologist** | **Survivorship Clinic**

impedimed®

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited.

Heart Health

- Building clinical and commercial momentum in the US outpatient heart failure monitoring market.
- 50% of heart failure patients are overweight or obese, and 20% of patients are at elevated sarcopenia risk, drawing connection to use of BodyComp alongside HF-Dex® for this patient population.
- Generating clinical evidence to support use of SOZO Pro in heart patients with frailty and SOZO correlation with market-leading implantable pulmonary artery pressure monitoring system.
- Expanding indications to additional cardiovascular conditions with latest FDA application.
- Collaborating with select device companies to conduct bench testing alongside active implantable technologies.




1.Bozkurt et al; Writing Committee Members. Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America. J Card Fail. 2023 Oct;29(10):1412-1451. doi: 10.1016/j.cardfail.2023.07.006. Epub 2023 Sep 26. PMID: 37797885; PMCID: PMC10864030.

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited.

Weight Management & Body Composition

- Addressing four key market segments where BodyComp clinical indications provide meaningful clinical relevance:
  - Primary/Preventive Care
  - Longevity & Wellness
  - Medically Managed Weight Loss
  - Sports Medicine & Research
- New Strategic KOL & distribution partnerships will extend visibility and reach across segments.
- Focused outreach alongside conference presence in Longevity, Wellness, Obesity Medicine, Lifestyle Medicine and Sports Medicine.
- Disciplined traction and increasing validation that we are addressing the right market segments.



1. Mozzafarian et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. The American Journalof Clinical Nutrition Volume 122, Issue 1, July 2025, Pages 344-36
The Obesity Society Applauds the Work of The Lancet Diabetes & Endocrinology Commission on Diagnostic Criteria of Clinical Obesity. The Obesity Society. January 2025
Optimal Resources for Metabolic and Bariatric Surgery. American College of Surgeons, 2022

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited.

Right Leadership Team:



Erik Anderson
Managing Director & CEO



Nicole Stout, DPT
Chief Clinical Innovation Officer



Erik Johnson
Head of Sales



Blake Ahitow
Sr. Director, Customer Success & Strategic Accts



Gina Kimball
Head of Commercial Ops



McGregor Grant
Executive Director & CFO



Scott Savage
Chief Product Officer



Julie Kuhlken
Sr. Director, Marketing



Chelsey Jaworski
VP, Market Access & Reimbursement



Ashley Munoz
Director, Human Resources

= joined <6 months ago

impedimed®

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited.

Introducing SOZO® Health

SOZO® Health is the pioneer and leader in
precision fluid and body composition technology.
We reveal meaningful health signals in the body before they can be seen or felt
with advanced bioimpedance spectroscopy (BIS) technology
that detects even the smallest physiological changes at the point of care. Because
earlier detection and intervention lead to healthier and longer lives.

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited.

The Future for SOZO® Health

We empower longer, healthier lives by revealing essential health insights that enable early, proactive intervention.

Our goal is to be THE trusted, essential vital sign for understanding fluid and body composition across the continuum of health and patient care



Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited.